Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19

Authors

DOI:

https://doi.org/10.18413/rrpharmacology.11.469

Abstract

Introduction: The article presents information on the dynamics of office blood pressure in patients with arterial hypertension stage II who have had COVID-19 during antihypertensive pharmacotherapy (AHPT), including the L-arginine complex (500 mg tablets once a day) + dihydroquercetin (25 mg tablets twice a day).

The aim was to improve the effectiveness of treatment of COVID-19-treated HD patients by pharmacoepidemiologic and clinical substantiation of inclusion of L-arginine + dihydroquercetin complex in the composition of combined AHPT.

Materials and Methods: In order to achieve the goal, we developed a research design, which involved two stages. During the 1st stage, we designed a questionnaire for pharmacy visitors, which in agreement with the management of pharmacies, pharmacists offered visitors to fill out when the latter buy antihypertensive officinal drugs (AHOD). The questionnaire survey of pharmacy visitors in Donetsk was conducted from December 2021 till February 2023. A total of 1118 pharmacy visitors with HD participated in the questionnaire survey. The 2nd stage of the study included HD patients who had undergone COVID-19. Patients who met the inclusion criteria and had no exclusion criteria were included in the study.

Results and Discussion. The proposed treatment has been shown to be more effective than standard antihypertensive pharmacotherapy. This is manifested by the achievement of normotonic values of office systolic and diastolic blood pressure by the end of the 2nd week of treatment (<140/90 mmHg) compared to standard antihypertensive pharmacotherapy, in which this result was achieved only by the end of the 4th week of treatment. A decrease in systolic blood pressure levels to <130 mm Hg and diastolic blood pressure to <80 mm Hg was achieved starting from the 4th week of treatment only when the L-arginine + dihydroquercetin complex was included in the combined antihypertensive pharmacotherapy.

Conclusion: Inclusion of L-arginine complex (500 mg tablets once a day, for 12 weeks according to the 2 weeks-on/1 week-off regimen) + dihydroquercetin (25 mg tablets twice a day, for 12 weeks according to the 4 weeks-on/1 week-off regimen) as a part of combined AHPT (including statins) in patients with stage II HD, who underwent COVID-19, increased its efficacy, which was manifested by achievement of normotonic values of office SAP and DAP (<140/90 mm Hg) by the end of the 2nd week of treatment compared to combined AHPT (including statins) in comparison with combined AHPT (by the end of the 4th week of treatment).

 

Graphical Abstract

Keywords:

arterial hypertension, COVID-19, combined antihypertensive pharmacotherapy, L-arginine, dihydroquercetin

References

Borghi C, Fogacci F, Agnoletti D, Cicero AFG (2022) Hypertension and dyslipidemia combined therapeutic approaches. High Blood Pressure and Cardiovascular Prevention 29(3): 221–230. https://doi.org/10.1007/s40292-022-00507-8 https://pubmed.ncbi.nlm.nih.gov/35334087/ [PubMed] [PMC]

Dąbrowska E, Narkiewicz K (2023) Hypertension and dyslipidemia: the two partners in endothelium-related. Crime Current Atherosclerosis Reports; 25 (9): 605-612. https://doi.org/10.1007/s11883-023-01132https://pubmed.ncbi.nlm.nih.gov/37594602/ [PubMed] [PMC]

Kukharchuk VV, Ezhov MV, Sergienko IV, Arabidze GG, Bubnova MG, Balakhonova TV, Gurevich VS, Kachkovsky MA, Konovalov GA, Konstantinov VO, Malyshev PP, Pokrovsky SD, Sokolov AA, Sumarokov AB, Gornyakova NB, Obrezan AG, Shaposhnik II, Antsiferov MB, Ansheles AA, Aronov DM, Akhmedzhanov NM, Barbarash OL, Boitsov SA, Voivoda MI, Galstyan GR, Galyavich AS, Drapkina OM, Duplyakov DV, Eregin SY, KarpovRS, Karpov YA, Koziolova NA, Kosmachev ED, Nebieridze DV, Nedogoda SV, Oleynikov VE, Ragino YI, SkibitskyVV, Smolenskaya OG, Filippov AE, Halimov YS, Chazova IE, Shestakova MV, Yakushin SS (2020) Diagnostics andcorrection of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VIIrevision. [Ateroskleroz i Dislipidemii] 1(38): 7–42. https://doi.org/10.34687/2219-8202.JAD.2020.01.0002 [in Russian]

Ezhov MV, Sergienko IV, Aronov DM, Arabidze GG, Akhmedzhanov NM, Bazhan SS, Balakhonova TV, Barbarash OL, Boytsov SA, Bubnova MG, Voevoda MI, Galyavich AS, Gornyakova NB, Gurevich VS, Drapkina OM, Duplyakov DV, Yeregin SY, Zubareva MY, Karpov R, Karpov YA, Koziolova NA, Konovalov GA, Konstantinov VO, Kosmacheva ED, Martynov AI, Nebieridze DV, Pokrovsky SN, Ragino YI, Skibitsky VV, Smolenskaya OG, Chazova IE, Shalnova SA, Shaposhnik II, Kukharchuk VV (2017) Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VI revision. The Journal of Atherosclerosis and Dyslipidemias 3(28) 5–22. [in Russian]

Ignatenko GA, Nalotov SV, Nalotova EN, Serdyuk EB, Alesinsky MM, Nalyotova OS, Korovka IA (2022) Endothelial dysfunction in hypertensive patients who have had COVID-19. Archive of Clinical and Experimental Medicine 2(31): 127–131. [in Russian]

Kosmas CE, Muñoz Estrella A, Sourlas A, Silverio D, Hilario E, Montan PD, Guzman E (2018) Inclisiran: A new promising agent in the management of hypercholesterolemia. Diseases 6 (3): 63. https://doi.org/10.3390/diseases6030063[PubMed] [PMC]

Lyakh YuE, Guryanov VG, Khomenko VN, Panchenko OA (2006) Analysis of Information in Biology, Medicine and Pharmacy Using the MedStat Statistical Package. Donetsk Publishing House of DonNMU, Donetsk, Russia, 214 pp. [in Russian]

Nalotova OS (2019) Hypertension Combined with Adaptation Disorder: Clinical Picture, Diagnosis and Treatment. Digital Printing House, Donetsk, Russia, 221 pp. [in Russian]

Nalotov SV, Nalotova EN, Sidorenko IA, Nalotova OS, Serdyuk EB, Belevtsova EL (2021) COVID-19-induced endothelial dysfunction and possible ways of pharmacological correction. University Clinic 4(41): 117–123. [in Russian]

Shalnova SA, Metelskaya VA, Kutsenko VA, Yarovaya EB, Kapustina AV, Muromtseva GA, Svinin GE, BalanovaYuA, Imaeva AE, Evstifeeva SE, Vilkov VG, Barbarash OL, Belova OA, Grinshtein YuI, Efanov AYu, Kalachikova ON, Kulakova NV, Rotar OP, Trubacheva IA, Duplyakov DV, Libis RA, Viktorova IA, Redko AN, Yakushin SS, Boytsov SA, Shlyakhto EV, Drapkina OM (2022) Non-high density lipoprotein cholesterol: A modern benchmark for assessing lipidmetabolism disorders. Rational Pharmacotherapy in Cardiology [Ratsional'naya Farmakoterapiya v Kardiologii] 18(4): 366–375. https://doi.org/10.20996/1819-6446-2022-07-01 [in Russian]

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 42(34): 3227–3337. https://doi.org/10.1093/eurheartj/ehab484 [PubMed]

Vorobyev PA, Momot AP, Zaitsev AA, Elykomov VA, Sychev DA, Krasnova LS, Vorobyev AP, Vasiliev SA, Vorobyeva NA (2020) Disseminated intravascular coagulation syndrome during COVID-19 infection. Therapy [Terapiya] 6(5): 25–34. https://doi.org/10.18565/therapy.2020.5.25-34 [in Russian]

Zolotovskaya IA, Kuzmin VP, Rubanenko OA, Shatskaya PR, Salasyuk AS (2022) Lipid profile of patients with arterial hypertension who underwent COVID-19: possibilities of drug therapy/LEADER. Rational Pharmacotherapy in Cardiology [Ratsional'naya Farmakoterapiya v Kardiologii] 18(3): 282–288. https://doi.org/10.20996/1819-6446-2022-06-08 [in Russian]

Author Contribution

Elena N. Naletova, V.K. Gusak Institute of Emergency and Reconstructive Surgery; Donetsk State M. Gorky Medical University of the Ministry

Doctor Habil. of Medical Sciences, Associate Professor, Processor of the Department of Pharmacology and Clinical Pharmacology named after Prof. I.V. Komissarov, M. Gorky Donetsk State Medical University, Donetsk, Russia; Senior researcher at the Department of Cardiology, V.K. Gusak Institute of Emergency and Reconstructive Surgery of the Ministry of Health of the Russian Federation, Dotentsk, Russia; e-mail: elena.nalotova@mail.ru; ORCID ID https://orcid.org/0009-0002-3480-2581. The author advised on the research idea, the concept and design of the study, analyzed the results and edited the text of the article.

Olga S. Naletova, Donetsk State M. Gorky Medical University

Doctor Habil. of Medical Sciences, Associate Professor, Processor of the Department of Pharmacology and Clinical Pharmacology named after Prof. I.V. Komissarov, M. Gorky Donetsk State Medical University, Donetsk, Russia; e-mail: olganalotova1989@gmail.com; ORCID ID https://orcid.org/0000-0002-3646-5227. The author advised on the research idea, the concept and design of the study, analyzed the results and edited the text of the article.

Elena B. Serdyuk, Donetsk State M. Gorky Medical University

Research assistant of the Department of Pharmacology and Clinical Pharmacology named after Prof. I.V. Komissarov, M. Gorky Donetsk State Medical University; Donetsk, Russia; e-mail: elena.98.98@internet.ru; ORCID ID https://orcid.org/0009-0005-0145-9715. The author took part in collecting data and analyzing the material.

Sergey V. Naletov, Donetsk State M. Gorky Medical University

Doctor Habil. of Medical Sciences, Professor, Head of the Department of Pharmacology and Clinical Pharmacology named after Prof. I.V. Komissarov, M. Gorky Donetsk State Medical University, Donetsk, Russia; e-mail: sergiy.nalotov@gmail.com; ORCID ID https://orcid.org/0000-0003-2980-0258. The author advised on the research idea, the concept and design of the study, analyzed the results and edited the text of the article.

Mikhail M. Alesinsky, Donetsk State M. Gorky Medical University

Candidate of Pharmaceutical Sciences, Associate Professor, Associate Professor of the Department of Pharmacology and Clinical Pharmacology named after Prof. I.V. Komissarov, M. Gorky Donetsk State Medical University, Donetsk, Russia;e-mail: naruto249945@mail.ru; ORCID ID https://orcid.org/0009-0004-9523-1676. The author took part in collecting data and analyzing the material.

Inna A. Sidorenko, Donetsk State M. Gorky Medical University

Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Pharmacology and Clinical Pharmacology named after Prof. I.V. Komissarov, M. Gorky Donetsk State Medical University, Donetsk, Russia; e-mail:sidorenkoina@mail.ru; ORCID ID https://orcid.org/0009-0005-0145-9715. The author took part in collecting data and analyzing the material.

Tatyana A. Tverdokhleb, Donetsk State M. Gorky Medical University

Candidate of Medical Sciences, Associate Professor of the Department of Pharmacology and Clinical Pharmacology named after Prof. I.V. Komissarov, M. Gorky Donetsk State Medical University, Donetsk, Russia; e-mail: tatjna89@mail.ru; ORCID ID https://orcid.org/0000-0003-4550-7852. The author took part in collecting data and analyzing the material.

Downloads

Published

28-03-2025

How to Cite

Naletova EN, Naletova OS, Serdyuk EB, Naletov SV, Alesinsky MM, Sidorenko IA, Tverdokhleb TA (2025) Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19. Research Results in Pharmacology 11(1): 36–48. https://doi.org/10.18413/rrpharmacology.11.469

Issue

Vol. 11 No. 1 (2025)

Section

Experimental Pharmacology

License

Copyright (c) 2025 Elena N. Naletova, Olga S. Naletova, Elena B. Serdyuk, Sergey V. Naletov, Mikhail M. Alesinsky, Inna A. Sidorenko, Tatyana A. Tverdokhleb

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)